Komal Reverse Osmosis System

The unique features of KOMAL Reverse Osmosis (RO) system allow you to produce high quality water consistently for a variety of applications. With their compact designs, simple operation and low maintenance, KOMAL system are perfect for your use.

Komal Purified Water (PW) System

Each plant for the production of purified water is custom made, whether its capacity is 100 l/h or over 25 m3 /h. Every plant is designed with the customer and all the design parameters in minute details and with the same passion and dedication towards building an effective, safe and reliable system. After all each customer has a different system requirement: An SME engaging in contact manufacture has need which differs from an international conglomerate. Thus no plant is entirely like any other. ALL KOMAL PW basic systems meet EP, USP and guidelines and ensure the production process, product quality and profitability. The GMP-compliant confirms to FDA and ISPE requirements.

Click here to see more Water Treatment plants

Rusty Nelson • (630) 776 - 2459 • Rnelson@djausa.com

Go to article: Home | Getting PersonalGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Novo NordiskGo to article: NewsGo to article: PhoenixGo to article: The Pharma Industry BriefingGo to article: Nelson Lab Company InsightGo to article: Nelson LabsGo to article: Manufacturing personalised meds: what needs to change?Go to article: Molnar Company InsightGo to article: MolnarGo to article: Selling cells: the economics of CAR-T therapyGo to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Using AI to personalise drug combination therapyGo to article: NSFGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Nipro PharmaPackagingGo to article: A summer of manufacturing disasters for Chinese pharmaGo to article: CapsugelGo to article: EndocaGo to article: ContraFect’s Staph infection drug may succeed in trial but caveats remainGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: Why are novel therapies for glioblastoma patients not gaining approvals?Go to article: Lubrizol Life SciencesGo to article: QualiMetriXGo to article: CAR-T approved in Europe but NICE verdict is divided: what happens next?Go to article: Palleos healthcare GmbH Go to article: Daiichi JitsugyoGo to article: EventsGo to article: Nemera Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Next issueGo to article: NemeraGo to article: Plastiape Go to article: General Electric Healthcare